|
US5116817A
(en)
|
1982-12-10 |
1992-05-26 |
Syntex (U.S.A.) Inc. |
LHRH preparations for intranasal administration
|
|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5244792A
(en)
|
1984-04-06 |
1993-09-14 |
Chiron Corporation |
Expression of recombinant glyoprotein B from herpes simplex virus
|
|
JPH0668B2
(ja)
|
1985-08-30 |
1994-01-05 |
財団法人化学及血清療法研究所 |
単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5804413A
(en)
|
1992-07-31 |
1998-09-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Herpes simplex virus strains for gene transfer
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
GB9415369D0
(en)
|
1994-07-29 |
1994-09-21 |
Lynxvale Ltd |
Mutant virus
|
|
US5855887A
(en)
|
1995-07-25 |
1999-01-05 |
The Regents Of The University Of California |
Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6071742A
(en)
|
1997-03-05 |
2000-06-06 |
Board Of Regents Of The University Of Nebraska |
Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
|
|
WO1998040475A1
(en)
|
1997-03-11 |
1998-09-17 |
Abbott Laboratories |
Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
AU8605598A
(en)
|
1997-07-31 |
1999-02-22 |
University Of Pittsburgh |
Targeted hsv vectors
|
|
US6989435B2
(en)
|
1997-09-11 |
2006-01-24 |
Cambridge University Technical Services Ltd. |
Compounds and methods to inhibit or augment an inflammatory response
|
|
AU742757C
(en)
|
1997-12-17 |
2007-05-17 |
Immunex Corporation |
Cell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
CZ302070B6
(cs)
|
1998-04-21 |
2010-09-29 |
Micromet Ag |
Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
EP0953639A1
(en)
|
1998-04-30 |
1999-11-03 |
Boehringer Ingelheim International GmbH |
FAPalpha-specific antibody with improved producibility
|
|
EP1002864A1
(en)
|
1998-11-10 |
2000-05-24 |
Universita' degli studi di Bologna |
HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
DK1141028T3
(da)
|
1998-12-23 |
2010-05-25 |
Pfizer |
Humane monoklonale antistoffer til CTLA-4
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
IL148079A0
(en)
|
1999-08-24 |
2002-09-12 |
Medarex Inc |
Human ctla-4 antibodies and compositions containing the same
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US6897057B1
(en)
|
1999-08-31 |
2005-05-24 |
The General Hospital Corporation |
Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
|
|
CA2386270A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
EP1261376A1
(en)
|
2000-01-27 |
2002-12-04 |
Genetics Institute, LLC |
Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
|
|
JP2003530092A
(ja)
|
2000-03-17 |
2003-10-14 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
ヒトＦＡＰ−α−特異抗体
|
|
PT1309726E
(pt)
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
|
US20040259247A1
(en)
|
2000-12-01 |
2004-12-23 |
Thomas Tuschl |
Rna interference mediating small rna molecules
|
|
CA2441663C
(en)
|
2001-03-27 |
2013-01-22 |
Medigene, Inc. |
Viral vectors and their use in therapeutic methods
|
|
CA2462790A1
(en)
|
2001-10-04 |
2003-04-10 |
Immunex Corporation |
Ul16 binding protein 4
|
|
KR100900249B1
(ko)
|
2001-12-07 |
2009-05-29 |
포항공과대학교 산학협력단 |
ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
|
|
BR0309254A
(pt)
|
2002-04-12 |
2005-03-01 |
Medarex Inc |
Uso de um anticorpo anti-ctla-4
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
US8927251B2
(en)
|
2002-10-07 |
2015-01-06 |
The University Of Chicago |
Targeting of herpes simplex virus to specific receptors
|
|
CN101928344B
(zh)
|
2002-10-17 |
2014-08-13 |
根马布股份公司 |
抗cd20的人单克隆抗体
|
|
US7563869B2
(en)
*
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
FI1897548T4
(fi)
|
2003-02-28 |
2024-09-03 |
The Johns Hopkins University |
T-solujen säätely
|
|
WO2004081021A2
(en)
|
2003-03-12 |
2004-09-23 |
Duke University |
Oligonucleotide mimetics
|
|
US7473418B2
(en)
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
|
EP1732600A2
(en)
|
2004-03-26 |
2006-12-20 |
Pfizer Products Incorporated |
Uses of anti-ctla-4 antibodies
|
|
CA2577692C
(en)
|
2004-08-20 |
2014-05-06 |
Viralytics Limited |
Methods and compositions for treatment of hematologic cancers
|
|
US20090252741A1
(en)
|
2004-09-08 |
2009-10-08 |
Ohio State University Research Foundation |
Human monoclonal anti-ctla4 antibodies in cancer treatment
|
|
WO2006050211A2
(en)
|
2004-10-28 |
2006-05-11 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
|
|
WO2006074526A1
(en)
|
2005-01-17 |
2006-07-20 |
Viralytics Limited |
Method and composition for treatment of neoplasms
|
|
PL2002003T3
(pl)
|
2005-05-27 |
2016-06-30 |
Ospedale San Raffaele Srl |
Wektor genetyczny zawierający mi-RNA
|
|
CN101355965A
(zh)
|
2005-06-08 |
2009-01-28 |
达纳－法伯癌症研究院 |
通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
DK1976886T3
(en)
|
2005-12-16 |
2015-03-02 |
Amgen Res Munich Gmbh |
Means and methods for the treatment of tumor diseases
|
|
JP2009521474A
(ja)
|
2005-12-21 |
2009-06-04 |
メディミューン，エルエルシー |
ＥｐｈＡ２ＢｉＴＥ分子およびその使用
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
JP6092497B2
(ja)
|
2006-03-30 |
2017-03-08 |
ユニバーシティー オブ カリフォルニア |
抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
|
|
AU2007266306A1
(en)
|
2006-05-26 |
2007-12-06 |
Apollo Life Sciences Limited |
An isolated IL-12 molecule or chimeric molecules thereof
|
|
CN101104640A
(zh)
|
2006-07-10 |
2008-01-16 |
苏州大学 |
抗人pd-l1单克隆抗体制备及应用
|
|
JP2008066402A
(ja)
|
2006-09-05 |
2008-03-21 |
Fujifilm Corp |
撮像素子および撮像装置
|
|
CA2663034C
(en)
*
|
2006-09-15 |
2016-05-03 |
Ottawa Health Research Institute |
Oncolytic rhabdovirus
|
|
EP2125032A4
(en)
|
2007-02-20 |
2011-02-23 |
Mayo Foundation |
CANCER TREATMENT WITH VIRAL NUCLEIC ACID
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
WO2008134878A1
(en)
*
|
2007-05-04 |
2008-11-13 |
University Health Network |
Compositions and methods for cancer treatment
|
|
US8586028B2
(en)
|
2007-05-09 |
2013-11-19 |
Board Of Supervisors Of Lousiana State University And Agricultural And Mechanical College |
Synthetic herpes simplex viruses type-1 for treatment of cancers
|
|
EP2212350B1
(en)
|
2007-10-26 |
2013-08-28 |
Governing Council of the University of Toronto |
Treating chronic viral infection by targetting TIM-3
|
|
WO2009100140A1
(en)
|
2008-02-04 |
2009-08-13 |
Medarex, Inc. |
Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
|
|
WO2009111892A1
(en)
|
2008-03-14 |
2009-09-17 |
Ottawa Health Research Institute |
Microrna mediated oncolytic targeting
|
|
EP2307033A4
(en)
|
2008-05-29 |
2012-06-13 |
Gen Hospital Corp |
USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
|
|
EP2700405B1
(en)
|
2008-05-29 |
2018-04-04 |
Alma Mater Studiorum -Universita' di Bologna |
Herpes simplex virus (HSV) with modified tropism, uses and process of preparation thereof
|
|
GB0810912D0
(en)
|
2008-06-13 |
2008-07-23 |
Inst Animal Health Ltd |
Vector
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
EP2406379A4
(en)
|
2009-03-13 |
2012-09-26 |
Egen Inc |
COMPOSITIONS AND METHODS FOR RELEASING BIOLOGICALLY ACTIVE RNA
|
|
ES2385251B1
(es)
*
|
2009-05-06 |
2013-05-06 |
Fundació Privada Institut D'investigació Biomèdica De Bellvitge |
Adenovirus oncolíticos para el tratamiento del cáncer.
|
|
US20100297072A1
(en)
|
2009-05-19 |
2010-11-25 |
Depinho Ronald A |
Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
|
|
CA2792561C
(en)
|
2010-04-06 |
2021-10-26 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of cd274/pd-l1 gene
|
|
WO2011125469A1
(ja)
|
2010-04-09 |
2011-10-13 |
国立大学法人東京大学 |
マイクロrna制御組換えワクシニアウイルス及びその使用
|
|
US9593347B2
(en)
|
2010-04-16 |
2017-03-14 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
|
|
JP2013532153A
(ja)
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
|
|
WO2012006181A2
(en)
|
2010-06-29 |
2012-01-12 |
Mount Sinai School Of Medicine |
Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
|
|
HUE036077T2
(hu)
|
2010-08-13 |
2018-06-28 |
Roche Glycart Ag |
Anti-FAP ellenanyagok és alkalmazásukra szolgáló eljárások
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
ES2704632T3
(es)
*
|
2011-09-08 |
2019-03-19 |
Univ New York |
Virus de herpes simplex oncolítico y sus usos terapéuticos
|
|
EP2591796A1
(en)
|
2011-11-10 |
2013-05-15 |
Universität Zürich |
Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
|
|
CA3101783C
(en)
|
2011-10-11 |
2023-01-31 |
Universitat Zurich Prorektorat Mnw |
Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
|
|
US11951157B2
(en)
|
2011-10-11 |
2024-04-09 |
Universitat Zurich |
Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
|
|
HUE059406T2
(hu)
|
2011-10-17 |
2022-11-28 |
Io Biotech Aps |
PD-L1 alapú immunterápia
|
|
US20130156808A1
(en)
|
2011-11-22 |
2013-06-20 |
Stipan Jonjic |
Vaccine comprising beta-herpesvirus
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
DK2806883T3
(da)
|
2012-01-25 |
2019-07-22 |
Dnatrix Inc |
Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
|
|
HK1204557A1
(en)
|
2012-05-31 |
2015-11-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-l1
|
|
US20150250837A1
(en)
*
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
WO2014138314A1
(en)
*
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
|
EP3447072A3
(en)
*
|
2013-03-05 |
2019-05-22 |
Baylor College of Medicine |
Engager cells comprising cd3 scfv and an antigen recognition domain that binds a tumor antigen for immunotherapy
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
ES3011466T3
(en)
|
2013-04-18 |
2025-04-07 |
Tilt Biotherapeutics Oy |
Enhanced adoptive cell therapy
|
|
US20160163211A1
(en)
|
2013-05-16 |
2016-06-09 |
Pearson Education, Inc. |
Accessible content publishing engine
|
|
CN106068326B
(zh)
|
2013-10-28 |
2021-06-18 |
联邦高等教育系统-匹兹堡大学 |
溶瘤性hsv载体
|
|
WO2015127501A1
(en)
|
2014-02-27 |
2015-09-03 |
Viralytics Limited |
Combination method for treatment of cancer
|
|
DK3169341T3
(da)
|
2014-07-16 |
2019-08-05 |
Transgene Sa |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
EP3204412B1
(en)
|
2014-10-08 |
2020-08-19 |
F.Hoffmann-La Roche Ag |
Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
|
|
WO2016115274A1
(en)
*
|
2015-01-14 |
2016-07-21 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
JP6954648B2
(ja)
|
2015-10-19 |
2021-10-27 |
シージー オンコロジー， インコーポレイテッド |
併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
|
|
EA201891022A1
(ru)
*
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
EP3778881A1
(en)
|
2016-01-08 |
2021-02-17 |
Replimune Limited |
Modified oncolytic virus
|
|
RU2749050C2
(ru)
|
2016-01-27 |
2021-06-03 |
Онкорус, Инк. |
Онколитические вирусные векторы и их применение
|
|
PL3426271T3
(pl)
|
2016-03-10 |
2025-11-24 |
Cg Oncology, Inc. |
Sposoby leczenia guzów litych terapią skojarzoną
|
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
JP7200104B2
(ja)
|
2016-08-01 |
2023-01-06 |
ヴァイロジン バイオテック カナダ リミテッド |
免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター
|
|
WO2018027316A1
(en)
|
2016-08-09 |
2018-02-15 |
Alkayyal Almohanad |
Oncolytic rhabdovirus expressing il12
|
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
|
US20190275092A1
(en)
|
2016-11-01 |
2019-09-12 |
Dnatrix, Inc. |
Combination therapy for treatment of brain cancers
|
|
EP3565578A1
(en)
|
2016-12-21 |
2019-11-13 |
Memgen LLC |
Armed replication-competent oncolytic adenoviruses
|
|
US11298420B2
(en)
|
2016-12-21 |
2022-04-12 |
Memgen, Llc |
Armed oncolytic viruses
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|